Pre-Made Baminercept Biosimilar, Fusion Protein targeting LTA fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting LT/TNFB/TNFSF1/TNLG1E for drug discovery and mechanism of action (MOA) research

Pre-Made Baminercept Biosimilar, Fusion Protein targeting LTA fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting LT/TNFB/TNFSF1/TNLG1E is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Baminercept is a lymphotoxin β receptor IgG fusion protein (LTβR-Ig), for the treatment of primary Sjögren's syndrome (SS). Primary Sjögren’s syndrome (pSjS) is characterized by chronic inflammation of the lacrimal and salivary glands, as well as frequent extra glandular involvement and increased risk of B cell lymphoma. Several lines of evidence implicate the lymphotoxin (LT) pathway in the pathogenesis of this disease. Baminercept inhibits the LT pathway, which is important in lymphoid tissue organization and chronic inflammation.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-749-1mg	1mg	3090
GMP-Bios-INN-749-10mg	10mg	Inquiry
GMP-Bios-INN-749-100mg	100mg	Inquiry
GMP-Bios-INN-749-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Baminercept Biosimilar, Fusion Protein targeting LTA fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting LT/TNFB/TNFSF1/TNLG1E
INN Name	Baminercept
Target	LTA
Format	Fusion Protein
Derivation	human
Species Reactivity	human
CH1 Isotype	Fusion - [LTBR (lymphotoxin beta receptor, TNFRSF3, tumor necrosis factor receptor superfamily (TNFR) member 3, TNFCR)]2 - IGHG1 Fc (Fragment constant)
VD LC	Fusion - [LTBR (lymphotoxin beta receptor, TNFRSF3, tumor necrosis factor receptor superfamily (TNFR) member 3, TNFCR)]2 - IGHG1 Fc (Fragment constant)
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Biogen, Inc. (Cambridge MA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0